The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. The Fool has written over 100 articles on Achillion Pharmaceuticals. Achillion Pharmaceuticals Stock Forecast: When you think of pharmaceutical companies, you may imagine Big Pharma companies with vast portfolios of drugs on the market and massive pipelines of … Alexion Pharmaceuticals will reportedly buy clinical-stage rival Achillion Pharmaceuticals in an all-cash deal. Learn more. Achillion Pharmaceuticals stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Buyout talk played a big role in several stocks' moves. Could This Be the Biggest US Gold Discovery in Years? Achillion Pharmaceuticals (ACHN) stock price, charts, trades & the US's most popular discussion forums. Check out our ACHN stock analysis, current ACHN quote, charts, and historical prices for Achillion Pharmaceuticals stock Our Accessibility Statement 79.42% of the stock of Achillion Pharmaceuticals … Wall Street Stock Market & Finance report, prediction for the future: You'll find the Achillion Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Achillion Pharmaceuticals's ACHN … United States The company's proven discovery and … Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. (Add your “underperform” vote.). Get short term trading ideas from the MarketBeat Idea Engine. What happened. (Add your “outperform” vote. Please log in to your account or sign up in order to add this asset to your watchlist. All news about Achillion Pharmaceuticals ... Uptrend Call Working As Achillion Pharma Stock Rises 7.8% (ACHN) May 07, 2020. Not a single company in this entire industry has ever gone out of business—ever. By Natalie Walters. Percentage Held by Insiders. In approximately 7 months, Achillion … Do Not Sell My Information. 79.42% of the stock of Achillion Pharmaceuticals is held by institutions. Market data powered by FactSet and Web Financial Group. Today's big jump continued the momentum from earlier this week when the biotech stock soared after … And are mandated by law to make a profit. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. There is not enough analysis data for Achillion Pharmaceuticals. The biopharmaceutical company can be reached via phone at 203-624-7000. Learn more. Through June 30, 2018, Achillion Pharmaceuticals has received approximately $932.4 million in aggregate gross proceeds from stock issuances, including convertible preferred stock, its initial public offering, private placements of its common stock, registered offerings of its common stock … Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Achillion Pharmaceuticals has received 492 “outperform” votes. In the past three months, Achillion Pharmaceuticals insiders have not sold or bought any company stock. Rigrodsky & Long, P.A. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. One share of ACHN stock can currently be purchased for approximately $6.76. Shares of Achillion Pharmaceuticals Inc. ACHN, -7.98% rocketed 82% in premarket trading Wednesday, after the biopharmaceutical company agreed to be acquired by Alexion Pharmaceuticals … Jul 7, 2016 10:44 AM EDT. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. 5,450 SmarTrend identified an Uptrend for Achillion Pharma (NASDAQ:ACHN) on October 16th, 2019 at $6.27. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The Investor Relations website contains information about Achillion Pharmaceuticals's business for stockholders, potential investors, and financial analysts. Industry: Biotechnology, VEVA Building #14 Suite 200 Earnings for Achillion Pharmaceuticals are expected to decrease in the coming year, from ($0.59) to ($0.71) per share. High institutional ownership can be a signal of strong market trust in this company. All rights reserved. The clinical-stage biotech didn't have any revenue in the first quarter. Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting. In the past three months, Achillion Pharmaceuticals insiders have not sold or bought any company stock. Health Care Why Is Achillion (ACHN) Down 11.2% Since Last Earnings Report? Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. These unique companies are almost always monopolies. By Bret Kenwell. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Primary metrics and data points about Achillion Pharmaceuticals. Achillion Pharmaceuticals Stock Soars on Deal to Be Acquired by Alexion Alexion Pharmaceuticals reached a deal to acquire Achillion Pharmaceuticals for $930 million, pending … Achillion Pharmaceuticals does not have a long track record of dividend growth. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Looking for new stock ideas? With oil drilling and fracking now dead money, investors are driving Green-Energy stocks to dizzying heights and getting rich along the way. Vote “Underperform” if you believe ACHN will underperform the S&P 500 over the long term. © American Consumer News, LLC dba MarketBeat® 2010-2021. Company profile page for Achillion Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information Achillion Pharmaceuticals, Inc. NASDAQ Updated Jan 1, 1970 12:00 AM ACHN 0.00 0.00 (0.00%). Wall Street analysts have given Achillion Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Great results from an early-stage clinical study provided a big boost to this small biotech. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. Achillion Pharmaceuticals, Inc. is a company in the U.S. stock market and it is a holding in 5 U.S.-traded ETFs. You can opt out at any time. A high-level overview of Achillion Pharmaceuticals, Inc. (ACHN) stock. ), Achillion Pharmaceuticals has received 445 “underperform” votes. And one last thing: the dividend yields are massive. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 But it made progress in several key areas. Fundamental company data provided by Zacks Investment Research. The biotech stock is enjoying a second day of big gains after the company reported promising results for experimental drug ACH-5228. MarketBeat just released five new trading ideas, but Achillion Pharmaceuticals wasn't one of them. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Analysts' Actions -- First Solar, Qualcomm, Red Hat, Zions and More. Achillion Pharmaceuticals has a P/B Ratio of 3.52. Achillion's interim data peek failed to impress investors. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. The official website for Achillion Pharmaceuticals is www.achillion.com. Sector: STOCKS. View which stocks are hot on social media with MarketBeat's trending stocks report. See how this tiny, unknown gold company secured a prime land package right next door to the world’s two largest gold producers in Nevada’s famed Carlin Trend where 84 Million gold ounces have already been extracted. Free forex prices, toplists, indices and lots more. 2019-09-07 zacks.com - 1 - A month has gone by since the last earnings report for Achillion Pharmaceuticals (ACHN - Free Report) . Export data to Excel for your own analysis. Percentage Held by Institutions. Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) were soaring 24.9% higher as of 11:16 a.m. EDT on Tuesday. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. “The acquisition of Achillion adds two clinical-stage Factor D inhibitors to our growing pipeline, representing important continued momentum in expanding and diversifying our portfolio and … View Achillion Pharmaceuticals' earnings history. Blue Bell, PA 19422 ... Uptrend Call Working As Achillion Pharma Stock Rises 7.8% (ACHN… The single most important factor in a company's success is the team that's leading the company, Why Achillion Pharmaceuticals, Tech Data, and First Majestic Silver Jumped Today, Why Achillion Pharmaceuticals Stock Is Skyrocketing Today, Why Achillion Pharmaceuticals Stock Is Jumping Today, Why Achillion Pharmaceuticals Stock Flew Higher Again Today, Why Achillion Pharmaceuticals Stock Is Soaring Again Today, Why Luckin Coffee, Beyond Meat, and Achillion Pharmaceuticals Jumped Today, Why Achillion Pharmaceuticals Stock Jumped Today, What You Need to Know About Achillion Pharmaceuticals' Q1 Update, Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December, Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day, Why Achillion Pharmaceuticals Sank Again Today, Why Achillion Pharmaceuticals Is Cratering Again Today, Why Achillion Pharmaceuticals Crashed Today, Copyright, Trademark and Patent Information. Did Hedge Funds Drop The Ball On Achillion Pharmaceuticals, Inc. (ACHN) ? Achillion Pharmaceuticals, Inc. () Stock Market info Recommendations: Buy or sell Achillion Pharmaceuticals stock? ACHN has around 100.9K shares in the U.S. ETF market. Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) flew 18% higher on Friday. The aftermath from its disappointing pipeline update early in the week continued to hurt the biotech stock. Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN.". Get daily stock ideas top-performing Wall Street analysts. Sr. VP of Regulatory Affairs, Quality & Compliance, Start Your Risk-Free Trial Subscription Here, Editor of top German newspaper suspended in compliance probe, Timing key in consulting deal between FirstEnergy, regulator, You Must Recognize Your Own Achievements First Before Expecting Others To, The Latest: Paris may face new lockdown as ICUs fill up, 'Big burden' for schools trying to give kids internet access, The Latest: Pakistan imposes partial lockdown in some areas, Three Mall Retailers For Your Reopening Watchlist, 3 Growth Stocks with Above Market Dividend Yields, 3 Best Stocks to Buy That You’ve Probably Never Heard Of, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight, 7 Stocks That Cathie Wood is Buying And You Should Too, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, Achillion Announces Pricing of Secondary Offering Of Common Stock, Achillion Reports First Quarter 2018 Financial Results and Management Transition, Lifshitz & Miller LLP Announces Investigation of Achillion Pharmaceuticals, Inc., Anixter International Inc., Central European, Achillion Appoints Nicholas Simon to Board of Directors, Achillion Pharmaceuticals (ACHN) - Options Chain, 14 Biotechnology Stocks Moving In Monday's Pre-Market Session, Achillion up 16% premarket on advancement of Alexion tie-up, Apellis' (APLS) PNH Drug Betters Alexion's Soliris in Study, Achillion shareholders back Alexion takeover. Learn about financial terms, types of investments, trading strategies and more. Vote “Outperform” if you believe ACHN will outperform the S&P 500 over the long term. document.write(''); Sign-up to receive the latest news and ratings for ACHN and its competitors with MarketBeat's FREE daily newsletter. Investors are responding enthusiastically to a key FDA designation for the biotech's leading pipeline candidate. To see all exchange delays and terms of use please see disclaimer. Reverberations from the biotech's pipeline update on Monday continued to weigh on the stock. ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Here’s a brand new clean energy innovator, currently undiscovered at $2 per share, that’s deploying a world’s-first business model with 10X to 20X upside. ACHN Stock Price (NASDAQ), Score, Forecast, Predictions, and Achillion Pharmaceuticals News. A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
Gabes Warehouse Morgantown, Wv Phone Number, Bolero Ravel Noten Pdf, Plötzlicher Kindstod Wer Hat Es Erlebt, Mordkommission Istanbul Neue Folgen 2019, Iman Pahlavi Instagram, F1 2021 Release, Zulassungsstelle Bruchsal Auto Abmelden, Die Zweite Spur, Angelplätze Am Main,
Neue Kommentare